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Abstract
Background: β-1→3-D-glucans represent a pathogen-associated molecular pattern and are able to modify
biological responses. Employing a comprehensive methodological approach, the aim of our in vitro study was to
elucidate novel molecular and cellular mechanisms of human peripheral blood immune cells mediated by a fungal
β-1→3-D-glucan, i.e. glucan phosphate, in the presence of lipopolysaccharide (LPS) or toxic shock syndrome toxin
1 (TSST-1).
Results: Despite an activation of nuclear factor (NF)κB, NFinterleukin(IL)-6 and NFAT similar to LPS or TSST-
1, we observed no significant production of IL-1β, IL-6, tumor necrosis factor α or interferon γ induced by glucan
phosphate. Glucan phosphate-treated leukocytes induced a substantial amount of IL-8 (peak at 18 h: 5000 pg/ml),
likely due to binding of NFκB to a consensus site in the IL-8 promoter. An increase in IL-1receptor antagonist(RA)
production (peak at 24 h: 12000 pg/ml) by glucan phosphate-treated cells positively correlated with IL-8 levels.
Glucan phosphate induced significant binding to a known NFIL-6 site and a new NFAT site within the IL-1RA
promoter, which was confirmed by inhibition experiments. When applied in combination with either LPS or
TSST-1 at the same time points, we detected that glucan phosphate elevated the LPS- and the TSST-1-induced
DNA binding of NFκB, NFIL-6 and NFAT, leading to a synergistic increase of IL-1RA. Further, glucan phosphate
modulated the TSST-1-induced inflammatory response via reduction of IL-1β and IL-6. As a consequence, glucan
phosphate shifted the TSST-1-induced IL-1β/IL-1RA ratio towards an anti-inflammatory phenotype. Subsequently,
glucan phosphate decreased the TSST-1-induced, IL-1-dependent production of IL-2.
Conclusion:  Thus,  β-1→3-D-glucans may induce beneficial effects in the presence of pro-inflammatory
responses, downstream of receptor binding and signaling by switching a pro- to an anti-inflammatory IL-1RA-
mediated reaction. Our results also offer new insights into the complex regulation of the IL-1RA gene, which can
be modulated by a β-1→3-D-glucan.
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Background
β-1→3-D-glucans occur as a principal component of
microbial cell walls or can be secreted from both, non-
pathogenic and pathogenic fungi such as S. cerevisae and
C. albicans [1]. These β-1→3-D-linked glucose polymers
are characterized as a fungal pathogen-associated molecu-
lar pattern (PAMP) [2]. The primary cellular recognition
of β-1→3-D-glucans is mediated by several β-1→3-D-glu-
can receptors on phagocytes [3,4] and other cells [5,6].
Human as well as murine Dectin-1 has been demon-
strated to be the major pattern recognition receptor (PRR)
for intact yeast and β-1→3-D-glucan-containing particles
(i.e. zymosan) on monocytes/macrophages as well as neu-
trophils and on primary cells [7-11]. In the murine sys-
tem, binding of zymosan to Dectin-1 resulted in
production of TNFα through Toll-like receptor 2 and the
adaptor protein MyD88 [12]. Another water-soluble β-
1→3-D-glucan (PGG-glucan) has been described to acti-
vate NFκB and NFIL-6 in murine cell lines [13,14]. Simi-
larly, it has been shown that β-1→3-D-glucans activate
NFκB in a human monocyte-like cell line [15] and in
human polymorphonuclear neutrophils (PMN), in the
latter case without secretion of pro-inflammatory
cytokines (IL-1, IL-6, TNFα) [16]. One study proposed
that the production of the anti-inflammatory IL-1RA, but
not IL-1 by human monocytes may be a potentially pro-
tective mechanism induced by β-1→3-D-glucan [17].
Three other investigations have reported that human leu-
kocytes and human vascular endothelial cells produce IL-
8 in response to zymosan [18] or a water-soluble β-1→3-
D-glucan [6,19].
In addition, β-1→3-D-glucans seem to be able to modify
the response to pro-inflammatory stimuli or even sepsis.
In a murine polymicrobial sepsis model, β-1→3-D-glucan
[20] treatment resulted in decreased septic morbidity and
mortality mediated via inhibition of NFκB and stimula-
tion of the phosphoinositide-3-kinase (PI3K) pathway
[21,22]. These and other animal studies [23,24] as well as
a clinical trial [25] support a protective role of β-1→3-D-
glucan in certain pro-inflammatory conditions. The
mechanisms underlying these beneficial effects of β-1→3-
D-glucan are only partially resolved, especially in
humans. Thus, the aim of this study was to elucidate
molecular and cellular mechanisms of β-1→3-D-glucans
on human leukocytes in pro-inflammatory conditions
with special emphasis on the cytokine profile and its tran-
scriptional regulation. For this purpose, peripheral blood
mononuclear cells (PBMC) were exposed to a well-
defined  β-1→3-D-glucan,  i.e. glucan phosphate (GP)
[20,26], alone or simultaneously with LPS from gram-
negative bacteria or the superantigen TSST-1 from gram-
positive bacteria over 48 h. Because of the potential effect
of β-1→3-D-glucan on cytokine production [12,16-19],
TNFα, IL-1β, IL-6, IL-8 and IL-1RA were measured as well
as IFNγ, IL-2, IL-4, IL-10, IL-12 and TGFβ1. Correspond-
ingly, four NFκB sites from the TNFα promoter (κ consen-
sus, κ1, κ2, κ3) [27], a κ consensus site from the IL-8
promoter [28], an NFAT site from the IFNγ promoter
(ATP2) [29] and a consensus NFIL-6 site from the IL-6
promoter [13] were examined. Because of the anti-inflam-
matory role of IL-1RA, we focused on binding of transcrip-
tion factors to the IL-1RA promoter. An inhibitory
element and three positive-acting LPS-response elements
(LRE-1, LRE-2 and LRE-3) in the IL-1RA promoter, includ-
ing NFκB, PU.1 and NFIL-6 sites, have been characterized
previously [30-33]. Using computational analysis for
homology search [34], we looked for new binding motifs
in the IL-1RA promoter.
Results
Binding activities of NFκB, NFIL-6 and NFAT from human 
PBMC to the TNFα, IL-6 and IFNγ promoters following an 
in vitro stimulation (1 h) with LPS, TSST-1, GP, GP + LPS 
and GP + TSST-1
GP induced band shifts, indicating binding of NFκB as
well as of NFIL-6 to the corresponding DNA oligonucle-
otides (κ consensus, κ1, κ2, κ3 sites from the TNFα pro-
moter;  κ consensus from the IL-8 promoter; NFIL-
6consensus from the IL-6 promoter; Table 1; Fig. 1A). The
extent of the band shifts induced by GP was not statisti-
cally different when compared to LPS or TSST-1 (Fig. 1B).
A supershift, conducted for an NFκB consensus site from
the IL-8 promoter, demonstrated a GP-induced predomi-
nant binding of NFκB p65 and to a lesser degree of p50
(Fig. 1A). Accordingly, an immunoblot of nuclear extracts
from GP-treated PBMC showed a strong binding of NFκB
p65 and a weaker reaction of p50, whereas p52 was nega-
tive (Fig. 2). Simultaneous co-treatment of PBMC with GP
did not change the LPS-induced NFκB binding to oligos
from the TNFα promoter significantly (Fig. 1B), but sub-
stantially decreased the TSST-1-induced NFκB binding
when compared to TSST-1 or GP (100 µg) and thus dif-
fered completely from the theoretical value of GP/TSST-1
calc. (n = 4; p < 0.05 vs. GP/TSST-1 calc. and p = 0.07 vs.
TSST-1; Fig. 1B). GP was also able to induce band shifts
indicative of binding of particular variants of NFAT to an
oligo from the IFNγ promoter (Fig. 1A). An immunoblot
for two NFAT subunits demonstrated a GP-induced bind-
ing of NFATc2 and to a lesser degree of NFATc1 (Fig. 2).
Cytokine profile of human PBMC following a 48 h in vitro 
stimulation with LPS, TSST-1, GP, GP + LPS and GP + 
TSST-1
Because of the GP-induced band shifts to seven sites from
the TNFα, IL-8, IL-6 and IFNγ promoters, it could be
assumed that GP treatment of human PBMC would lead
to production of TNFα, IL-8, IL-6, IFNγ and other pro-
inflammatory mediators. Previous studies reported that β-
1→3-D-glucans induced only a limited cytokine secretionBMC Immunology 2006, 7:5 http://www.biomedcentral.com/1471-2172/7/5
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of human blood cells [15-18]. Corroborating and extend-
ing these singular findings in terms of examining pro-
(eight) as well as anti- (three) inflammatory cytokines
over time (48 h) and six additional transcription factor
binding sites, our comprehensive analysis revealed the
following cytokine profile of human leukocytes in
response to a highly purified water soluble β-1→3-D-glu-
can and in comparison to two pro-inflammatory media-
tors (LPS, TSST-1):
(i) IL-1β
There was no IL-1β production detectable following
PBMC treatment with 1 nor 100 µg GP. An insignificant
up-regulation of IL-1β production for GP + LPS was
observed in comparison with LPS. For GP + TSST-1 we
found a significant reduction in IL-1β from 18 h – 24 h,
for the latter by about 40% when compared to TSST-1 or
the theoretical value of GP/TSST-1 calc. (n = 6; both p =
0.01). On the whole, GP mediated a reduction of the
TSST-1-induced amount of IL-1β by about 50% (Fig. 3A).
(ii) IL-6
GP induced only a small amount of IL-6 and there was no
significant alteration of the LPS-induced IL-6 production
by GP. On the contrary, we observed a decreased IL-6 pro-
duction for GP + TSST-1 when compared to TSST-1 or GP/
TSST-1 calc., especially at 24 h by about 40% (n = 5; both
p = 0.02), (data not shown in detail).
(iii) IL-8
We found that GP induced a substantial IL-8 production,
in comparison with medium control, especially at 24 h (n
= 13; p < 0.01). A combination of GP and LPS resulted in
a non-significant increase of IL-8 production when com-
pared to LPS or GP/LPS calc. There was no significant
alteration in IL-8 production following GP + TSST-1 when
compared to TSST-1 or GP/TSST-1 calc. (data not shown
in detail).
(iv) IL-1RA
Besides IL-8, IL-1RA was the only mediator which was
produced in significant quantities following GP treat-
ment, especially at 24 h (n = 14, p < 0.01). When com-
pared to LPS stimulation or GP/LPS calc., GP + LPS did
not alter the kinetic course of the IL-1RA production.
However, following GP + TSST-1 we found a synergistic
increase in IL-1RA production from 18 h to 48 h, when
compared to TSST-1 (for instance at 24 h: n = 6; p = 0.01)
or to the theoretical value of GP/TSST-1 calc. (from 18 h
to 36 h). Over the time course of 48 h, GP elevated the
TSST-1-induced amount of IL-1RA by approximately
200% (Fig. 3B).
Positive correlation between GP-induced IL-8 and IL-1RA pro-
ductions. Following stimulation with GP (24 h), we
observed a positive correlation between IL-8 and IL-1RA.
Moreover, we found this correlation to be dose-depend-
ent, since 100 µg of GP induced larger amounts of IL-8
Table 1: Sense strand of oligonucleotides used in EMSAs.
Oligonucleotidesa Base sequences (5'- XXX -3') binding site/cytokine gene promoter
(position of the cytokine gene from the TSS)b
NFκBcS GAT CCT CAG AGG GGA CTT TCCc GAT G NFκB consensus sequence/TNFα promoter [27]
NFκB1S GAT CCT GGG ACA GCC CAG NFκB1 sequence/TNFα promoter [27]
NFκB2S GAT CCG GGG TAT CCT G NFκB2 sequence/TNFα promoter [27]
NFκB3S GAT CCT GGG TTT CTC CGN F κB3 sequence/TNFα promoter [27]
IL-8κBcS ATC GTG GAA TTT CCT CTG A NFκB consensus sequence/IL-8 promoter [28]
NFATP2S GAT CTA AAA TTT CCA GTC CTT GA NFATP2 sequence/IFNγ promoter [29]
NFIL-6S TGC AGA TTG CGC AAT CTG CA NFIL-6 consensus sequence/IL-6 promoter [13]
NFκBcS GCG AGG AGG GTA TTT CCG CTT between -80 and -100 NFκB
consensus/IL-1RA promoter [30]
NFκB3S ACA ACA GCA AGG GTT TCT CTT TTT GGA AAT between -100 and -130 
NFκB3/IL-1RA promoter
NFκBcS AGT AGG GAG TTT GGT between -266 and -280 
NFκB consensus sequence/IL-1RA promoter
NFκB2/3S ACT CTG GGT ACC TGT between -288 and -302 
NFκB2/3 sequence/IL-1RA promoter
NFATP2/3S GGC GCA CAA AAC CTA AAA TAT TTA CTA TCT between -471 and -500
NFATP2/3 sequence/IL-1RA promoter
NFIL-6S TTA CAA CAC TCC ATT GCG ACA CTT AGT GGG between -140 and -170
NFIL-6 sequence/IL-1RA promoter [31]
Oct-1 DNAS AAT TGC ATT GCC TGC AGG TCG ACT CTA GAG GAT 
CCA TGC AAA TGG ATC CCC GGG TAC CGA GCT C
exclusion of unspecific bindings, unrelated DNA, (Amersham 
Pharmacia)
(a: S = sense; b: TSS = transcription start site;c: ___ = main binding motif).BMC Immunology 2006, 7:5 http://www.biomedcentral.com/1471-2172/7/5
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A, GP led to DNA binding of NFAT, NFκB and NFIL-6 Figure 1
A, GP led to DNA binding of NFAT, NFκB and NFIL-6. Human PBMC were incubated with medium control or GP (1 
and 100 µg) for 1 h at 37°C. Nuclear extracts were incubated with a 32P-labeled NFAT, NFκB, NFIL-6 or NFκB-IL-8 oligonu-
cleotide probe corresponding to the IFNγ, TNFα, IL-6 and IL-8 gene promoters (Table 1). Arrows with the black head indicate 
migrational location of the NFAT-DNA, NFκB-DNA, NFIL-6-DNA or NFκB-IL-8-DNA complex compared to free probe (no 
shift). Arrow with the open head indicates a supershift of NFκB-IL-8-DNA-anti-p65 and -p50, respectively. An autoradiogram 
from a representative experiment is shown (n = 7). B, Decreased DNA binding of NFκB following GP + TSST-1, com-
pared to TSST-1, GP, or TSST-1/GP. Human PBMC were incubated with medium control, LPS, TSST-1, GP (100 µg), GP 
+ TSST-1 and GP + LPS for 1 h at 37°C. An autoradiogram from a representative experiment is shown. Schematic representa-
tion of NFκB-DNA binding activity following GP (1 and 100 µg) or TSST-1 treatment (250 ng) as well as simultaneous adminis-
tration of both compounds and the theoretical value (GP/TSST-1 calc.). Medium control levels were set equal to 1± SEM and 
significances (* = p < 0.05) are shown with respect to medium control (n = 4).
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and IL-1RA than 1 µg GP (n = 5, p ≤ 0.002, r = 0.9 and
0.98, respectively).
(v) TNFα
With respect to TNFα production, 100 µg of GP yielded
minor, statistically not distinguishable amounts, when
compared to medium control. GP + LPS did not change
the TNFα production when compared to LPS supplemen-
tation or GP/LPS calc. When combined with TSST-1 or
GP/TSST-1 calc., GP seemed to exert a synergistic effect on
TNFα secretion after 36 h (n = 3; p < 0.05), but overall an
enhancement of only 10% was observed (p > 0.05; data
not shown in detail).
(vi) IFNγ
No IFNγ production was detectable following treatment
of PBMC with 100 µg GP. There was a minor increase in
IFNγ production following GP + LPS at 36 h, when com-
pared to LPS or GP/LPS calc., and a slight down-regulation
following GP + TSST-1 at 24 h and 36 h, when compared
to TSST-1 or GP/TSST-1 calc. (data not shown).
(vii) IL-2, IL-12, IL-4, IL-10, TGFβ1
The production of IL-2, IL-12, IL-4, IL-10 and TGFβ 1 was
not induced by GP. There were also no significant differ-
ences between medium control, LPS, TSST-1, GP, GP +
LPS, GP/LPS calc. and GP + TSST-1 or GP/TSST-1 calc. over
48 h (data not shown).
NFκB p65/p50 and NFATc2/c1 were involved in GP-induced DNA binding Figure 2
NFκB p65/p50 and NFATc2/c1 were involved in GP-induced DNA binding. In order to determine whether the DNA 
binding proteins activated by GP were related to NFκB and NFAT, an immuno(dot) blot was performed. A representative dot 
blot showing staining of negative and positive controls (recombinant proteins NFκB p52, c-rel; nuclear extracts of PMA-treated 
Jurkat cells positive for NFκB p50, p65 and for NFATc1, c2) in the upper panel and staining of nuclear extracts of GP-treated 
PBMC (positive for NFκB p65, p50 and NFAT c2, c1) in the lower panel is shown (n = 3).
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A, IL-1β was down-regulated (12 h – 24 h) following GP + TSST-1 when compared to TSST-1 Figure 3
A, IL-1β was down-regulated (12 h – 24 h) following GP + TSST-1 when compared to TSST-1. Time course (48 h) 
of IL-1β production (pg/ml) by human PBMC incubated with medium control, 100 µg GP, 250 ng TSST-1, GP + TSST-1, 250 ng 
LPS and GP + LPS. At 18 h and 24 h there was a marked reduction in IL-1β production following GP + TSST-1 when compared 
to TSST-1 (* = p < 0.05). Graphs depicting the theoretical values for GP/LPS calc. and GP/TSST-1 calc. are also shown. IL-1β 
levels in the supernatnant were obtained by Elisa and are shown as mean ± SEM (n = 3). B, IL-1RA was exaggerated fol-
lowing GP + TSST-1 (12 h – 48 h) when compared to TSST-1. Time course (48 h) of IL-1RA production (pg/ml) by 
human PBMC incubated with medium control, 100 µg GP, 250 ng TSST-1, GP + TSST-1, 250 ng LPS and GP + LPS. Between 18 
h and 48 h a simultaneous treatment of PBMC with GP + TSST-1 led to a synergistic effect, i.e. a higher IL-1RA production 
when compared to an addition of the single values for TSST-1 and GP (* = p < 0.05). Graphs depicting the theoretical values 
for GP/LPS calc. and GP/TSST-1 calc. are included. IL-1RA levels in the supernatnant were obtained by Elisa and are shown as 
mean ± SEM (n = 3).
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Role of NFκB, NFIL-6 and NFAT binding in LPS-, TSST-1-, 
GP-, GP + LPS- and GP + TSST-1-induced IL-1RA 
expression by human PBMC
Because GP induced band shifts to NFκB, NFIL-6 and
NFAT sites, but no TNFα, IL-6 or IFNγ, we hypothesized
that the activated transcription factors might bind to sites
in the IL-1RA promoter. We investigated previoulsy
described and newly discovered transcription factor bind-
ing sites of the IL-1RA promoter (Table 1) using the pro-
gram OMIGA (v.1.1.3, Oxford Molecular, Oxford, UK).
The LPS responsive κB consensus site of LRE-1 (between -
84 and -93) [30] displayed band shifts, but no significant
alterations of its binding activity, irrespective of the treat-
ment (data not shown). A new κB3 site (-100 and -130)
within the LRE-1 [30] showed increased binding induced
by TSST-1 (+30% vs. control), but GP co-treatment up-
regulated the LPS (+65% vs. control)- and the TSST-1
(+110% vs. control)-induced binding in a superadditive
synergistic fashion, when compared to medium control as
well as to LPS, TSST-1 or GP or the theoretical values of
GP/LPS calc. or GP/TSST-1 calc. (all p < 0.05; Fig. 4). Bind-
ing to a new κB consensus site (between -266 and -280)
was significantly elevated for GP + TSST-1 (p < 0.05; data
not shown). The LPS-, TSST-1- and GP + LPS-induced
binding to the new κB2/3 site (-288 and -302) was down-
regulated by about 20–35% in comparison with medium
control (p < 0.05; data not shown). The NFIL-6 site (-147
and -170) close to LRE-2 [31,32] showed an up-regulation
of binding for all compounds and combinations vs.
medium control, ranging from 25–110% (p < 0.05). Fur-
ther, GP + TSST-1 induced an increased binding to the
NFIL-6 site in comparison with TSST-1 (1.3fold) or GP
(1.6fold; p < 0.05), (data not shown). A new binding site
for NFATP2/3 was found more distal of the transcription
start site, between -471 and -490, displaying again a sub-
stantial increase of binding for all compounds and com-
binations, when compared to medium control (p < 0.05).
In addition, binding to the NFATP2/3 site following both,
GP + LPS (1.4fold of GP) and GP + TSST-1 (1.5fold of GP,
1.25fold of TSST-1) was elevated (p < 0.05; Fig. 5), but
only in an additive synergistic manner, i.e. the experimen-
tal results were not different from the theoretical values
(calc.).
GP modulated the TSST-1-induced IL-1β/IL-1RA ratio 
towards an anti-inflammatory phenotype
In a simplified approach, IL-1β and IL-1RA might repre-
sent two sides of a coin, i.e. pro- or anti-inflammatory
action. Therefore, we applied the IL-1β/IL-1RA ratio as an
indicator of the degree of inflammation. Both, LPS and
GP + LPS treatments resulted in generating more IL-1β
than IL-1RA at early time points, i.e. up to 24 h. Compar-
ing LPS vs. GP + LPS, we did not find substantial altera-
tions over a time course of 48 h in the IL-1β/IL-1RA ratio,
only a – non-significant – 2.5fold higher ratio at 6 h. With
respect to TSST-1 or the theoretical value of GP/TSST-1
calc. vs. GP + TSST-1, we observed a pronounced anti-
inflammatory action of GP, as demonstrated by an about
10–100 fold reduced ratio at 18 h and 24 h of incubation,
i.e. a higher production of IL-1RA than of IL-1β (n = 3;
both p < 0.05; Fig. 6). A biological relevance of this result
was suggested by a decrease of the IL-1 dependent release
of IL-2 from murine EL-4 cells following GP + TSST-1
when compared to TSST-1 or GP/TSST-1 calc. (data not
shown in detail, n = 4; p < 0.07).
Inhibition of transcription factors led to reduced IL-1RA 
levels
Pharmacological inhibitors were used to demonstrate that
the transcription factor sites within the IL-1RA promoter
are relevant for the induction of IL-1RA by GP. As
expected, an inhibition of NFκB via CAPE [35] and CyA,
NFAT via CyA and NFIL-6 via CHX [36] could not be over-
ruled by GP, leading to a down-regulated binding activity
of the transcription factors to the IL-1RA sites, and a
reduction of IL-1RA mRNA and IL-1RA protein levels (Fig.
7). The extent of reduction in NFATP2/3 binding is exem-
plarily shown in an autoradiogram (Fig. 7A, left side) and
graphically summarized (n = 4, Fig. 7A, right side). The
results for the NFκB and NFIL-6 binding sites were similar
(data not shown). Because the highest IL-1RA amount was
found at 24 h, mRNA was examined following 1 h inhibi-
tion and 18 h of GP. A representative gel demonstrating a
GP modulated LPS- and TSST-1-induced binding to a new  NFκB3 site in the IL-1RA promoter Figure 4
GP modulated LPS- and TSST-1-induced binding to a 
new NFκB3 site in the IL-1RA promoter. Binding was 
enhanced for GP + LPS and GP + TSST-1, when compared to 
LPS, TSST-1, GP, GP/LPS calc. or GP/TSST-1 calc., respec-
tively (* = p < 0.05; ** = p < 0.01). Medium control levels 
were set equal to 1 ± SEM (n = 6). DNA binding was 
assessed by EMSA (see methods).
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decrease in IL-1RA mRNA after inhibition with CAPE, CyA
and CHX is displayed in Fig. 7B (n = 4). In addition, cor-
responding IL-1RA protein levels after 24 h of GP are
shown in Fig. 7C (n = 3). Altogether, NFκB inhibition by
CAPE was more pronounced at the binding activity and
the transcription, whereas CyA and CHX mainly led to a
decreased IL-1RA release.
Discussion
Animal models of sepsis and myocardial injury suggest
that a β-1→3-D-glucan like GP mediates its protective
mechanisms, in part, via a rapid shift from NFκB- to PI3K-
signaling [22,37]. Our study provides novel evidence that
downstream of recognition and signaling pro-inflamma-
tory transcription factor binding and cytokine expression
of human leukocytes is switched to an anti-inflammatory
phenotype by GP.
We confirmed and extended previous results [13-16] indi-
cating that, in the absence of other stimuli, β-1→3-D-glu-
cans induced binding of NFκB-, NFIL-6- and NFAT-mers
to cytokine promoters. Because of the multiple band shifts
observed for NFAT binding (Fig. 1A), one could speculate
that there is activation of several different NFAT isoforms,
probably derived from alternative splicing [38]. Interest-
ingly, the GP-induced transcription factor binding trans-
formed only into a very limited cytokine response,
namely IL-8 and IL-1RA (Fig. 3B). Hence, our data are in
aggreement with the few reports describing a β-1→3-D-
glucan-mediated IL-8 [6,16,19] and IL-1RA production
[17]. In addition, our EMSA/supershift and immunoblot-
ting results demonstrated a GP-mediated predominant
binding of NFκB p65 and to a lesser extent of p50 to a κB
consensus site of the IL-8 promoter (Figs. 1A, 2). Results
by Schulte and colleagues [28] pointed to an induction of
IL-8 transcription depending on activation via an NFκB
p65/65 homodimer, rather than via p65/50 heterodimers,
which might be the case for the GP-mediated IL-8 tran-
scription. A GP-mediated IL-8 transcription based upon a
cooperation between transactivated NFκB p65 and NFIL-
6 [13,39] or NFATc2 dimer binding to the IL-8κB site [38]
seems also possible. The IL-8κB consensus site exhibits a
preferentially p65 binding half site and thus differs from
the κB half site described for TNFα and IL-1β [27,40], sup-
porting the idea of regulating NFκB binding through com-
binatorial associations of the subunits and the specific
sequence of the decameric κB motif [41,42]. Unlike LPS or
TSST-1, we found that GP did not induce IL-1β, but it
strongly induced IL-1RA, suggesting an immediate anti-
inflammatory potential of GP. Analysing the IL-1RA pro-
moter [34], we discovered four new binding sites (Fig. 8):
an NFκB3 site (between -100 and -130), an NFκB consen-
sus site (-266 and -280), another NFκB2/3 site (-288 and
-302) and a more distal NFATP2/3 site (-471 and -490).
Our data indicated that GP leads to production of IL-1RA
primarily via induction of NFATP2/3 and NFIL-6 DNA
binding, which might be due to differences in the binding
motif or the composition of the activated transcription
factors (NFAT) between the IFNγ, IL-6 and IL-1RA pro-
moter. The differential decrease of NFκB, NFAT and NFIL-
GP modulated TSST-1-induced DNA binding to a new  NFATP2/3 site in the IL-1RA promoter Figure 5
GP modulated TSST-1-induced DNA binding to a 
new NFATP2/3 site in the IL-1RA promoter. Binding 
was up-regulated for GP + LPS and GP + TSST-1, when com-
pared to GP and, in the latter case, to both GP and TSST-1 (* 
= p < 0.05). Human PBMC were incubated with medium con-
trol, LPS, TSST-1, GP, GP + TSST-1 and GP + LPS for 1 h at 
37°C. Schematic representation of the elevated NFAT-DNA 
binding activity to the site in the IL-1RA promoter. Bars 
depicting the theoretical values for GP/LPS calc. and GP/
TSST-1 calc. are added. Medium control levels were set 
equal to 1 ± SEM (n = 6). An autoradiogram of a representa-
tive experiment is shown in the lower panel (lane 1: water; 
lane 2: medium control; lane 3: GP; lane 4: LPS; lane 5: TSST-
1, lane 6: GP + LPS; lane 7: GP + TSST-1).
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6 binding to sites in the IL-1RA promoter as well as of IL-
1RA mRNA and protein induced by selective inhibitors
prior to GP treatment might suggest that these steps are
linked to each other and necessary for induction of IL-1RA
(Fig. 7). Regarding cellular sources, both, monocytes as
well as neutrophils have been reported to produce IL-1RA
[32]. Flow cytometric experiments seemed to confirm that
monocytes and neutrophils were able to produce IL-8 just
as IL-1RA in response to GP (data not shown). This GP-
induced cytokine profile was substantially more restricted
than that of LPS or TSST-1, which is likely due to differ-
ences in recognition and signaling between LPS, TSST-1
and GP. Recognition of LPS is mainly mediated through
Toll-like receptor 4 and subsequent signaling via the NFκB
Decreased IL-1β/IL-1RA ratio following GP + TSST-1 when compared to TSST-1 Figure 6
Decreased IL-1β/IL-1RA ratio following GP + TSST-1 when compared to TSST-1. Time course (48 h) of the IL-1β/
IL-1RA ratio following incubation of human PBMC with LPS, TSST-1, GP + LPS, GP/LPS calc., GP + TSST-1 or GP/TSST-1 calc. 
LPS and GP + LPS treatments resulted in generating more IL-1β than IL-1RA up to 24 h. When comparing LPS or GP/LPS calc. 
vs GP + LPS we did not find significant alterations in the IL-1β/IL-1RA ratio over 48 h. With respect to TSST-1 or GP/TSST-1 
calc. vs GP + TSST-1 we observed a pronounced anti-inflammatory action of GP, as demonstrated by an about 10–100 fold 
reduced ratio at 18 h and 24 h, i.e. a higher production of IL-1RA than of IL-1β (* = p < 0.05). Data are shown as mean ± SEM 
(n = 3).
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Inhibition of GP-induced NFκB, NFAT and NFIL-6 DNA binding to the IL-1RA promoter Figure 7
Inhibition of GP-induced NFκB, NFAT and NFIL-6 DNA binding to the IL-1RA promoter. A, A representative 
autoradiogram (lane 1: control, lane 2: GP, lane 3: GP + unlabeled mutated NFATP2/3 oligo, lane 4: GP + CAPE, lane 5: GP + 
CyA, lane 6: GP + CHX, lane 7: GP + unlabeled NFATP2/3 oligo, lane 8: water) as well as a graphical summary for the 
NFATP2/3 site, depicting a decrease in binding following inhibition when compared to GP is displayed (* = p < 0.05). Data are 
shown as mean ± SEM (n = 4). B, Inhibition of NFκB, NFAT and NFIL-6 resulted in decreased IL-1RA mRNA following CHX, 
CAPE or CyA compared to GP. GAPDH is used as housekeeping control (representative gel, n = 4). C, Inhibition of NFκB, 
NFAT and NFIL-6 significantly reduced the production of IL-1RA by human PBMC following treatment with CHX, CAPE or 
CyA when compared to GP (* = p < 0.05; ** = p < 0.01). Data are shown as mean ± SEM (n = 3).
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pathway, leading to expression of pro-inflammatory
mediators like TNFα [43]. A bacterial superantigen like
TSST-1 acts through binding to MHC-II molecules and
subsequently the T cell receptor, leading to release of
mainly IFNγ and TNFα, the latter via both, PI3K and p38
mitogen-activated kinase signaling [44,45]. Altogether,
the induction of the neutrophil-attracting IL-8 and the
anti-inflammatory IL-1RA by fungal carbohydrates (GP)
may well fit to a benign PAMP response, mounting defen-
sive mechanisms against a possible microbial attack.
Potentially even more relevant than the specific cytokine
panel induced by GP, we found that, in the presence of
other stimuli (LPS or TSST-1), GP ameliorated their pro-
inflammatory immune reactions, similar to the effects in
murine models of sepsis and inflammation [21-24].
Mainly, GP altered the TSST-1-induced IL-1β/IL-1RA ratio
from a pro- to an anti-inflammatory profile via down-reg-
ulation of IL-1β and IL-6, at the same time there was a syn-
ergistic up-regulation of IL-1RA. In part, this change may
be caused by GP-mediated modulations of the TSST-1
induced binding of NFκB, NFIL-6 and NFAT to known
and up to now unknown sites within the IL-8 and IL-1RA
promoter instead of the TNFα, IL-1β, IL-6 or IFNγ pro-
moter. Accordingly, we found that the TSST-1-induced
binding of NFκB to sites from the TNFα promoter nega-
tively correlated with the GP-mediated enhancement of
the TSST-1-induced IL-1RA production (r = -0.88; p <
0.01; data not shown in detail). Of the four examined
NFκB sites from the IL-1RA promoter, mostly the TSST-1-
and LPS-induced binding to the NFκB3 and the TSST-1-
induced binding to the new NFκB consensus site seemed
to be increased by GP. So, while we observed a GP-medi-
ated down-regulation of the LPS- and the TSST-1-induced
NFκB binding to sites of the TNFα promoter, there was an
up-regulation to NFκB3 and NFκB consensus sites of the
IL-1RA promoter. These seemingly contradictory data
could be explained by differences in either NFκB subunits
or conserved nucleotides (#1, 2, 3, 10) within the deca-
meric NFκB binding motif between the TNFα and the IL-
1RA promoter (for NFκB3 the IL-1RA motif contains a T
on position 10 instead of the conserved C in the TNFα
motif, see Table 1), probably leading to differences in
binding [41,42]. Despite the location of the new NFκB
consensus site (-266 and -280) in the inhibitory element
(-250 and -294) of the IL-1RA promoter [30], we observed
no inhibition. On the other side, we found an inhibitory
NFκB2/3 site (-288 and -302) towards the end of the
inhibitory element, demonstrating down-regulations of
the LPS- and TSST-1-induced binding, which could not be
altered by GP. In our opinion, this site may therefore rep-
resent at least a part of the previoulsy described inhibitory
element [30]. The GP-modulated increase in TSST-1-
induced binding to the new NFκB3 and NFκB consensus
site, the NFIL-6 site [32] as well as to the novel NFATP2/3
site may explain the synergistic up-regulation of the TSST-
1-induced IL-1RA production. We think that this GP-
modulated activation of transcription was reflected by the
decrease of the IL-1β/IL-1RA ratio following GP + TSST-1
(Fig. 6). In this context, it has been postulated that in vitro
a 100fold excess of IL-1RA over IL-1β might control the
biological effects of IL-1 [46,47]. Since, in fact, the IL-1β/
IL-1RA ratio following GP + TSST-1 is partially less than
0.01, it is not unreasonable to assume that IL-1β bioactiv-
Cartoon of the sense strand of the IL-1RA promoter Figure 8
Cartoon of the sense strand of the IL-1RA promoter. Relative locations of previously (LRE-1) [30-33] and newly 
described (boxed), positively (black) and negatively (gray) regulatory transcription factor binding sites are depicted.
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ity is inactivated in our system. Indeed, GP reduced the
TSST-1-induced, IL-1-dependent IL-2 production of
murine EL-4 cells (data not shown in detail).
The weaker modulating effects of GP on the LPS-induced
immune response observed in this study, may be attrib-
uted to delicately balanced differences in signaling path-
ways between LPS and TSST-1 [43-45]. TSST-1 has been
shown to use the PI3K pathway for signaling [44] and this
effect may be sustained by GP treatment [22,37]. It has
been demonstrated that in septic/LPS-adapted leukocytes
the PI3K pathway selectively controls sIL-1RA but not IL-
1β production [48]. Signaling via PI3K has been reported
to be involved in the activation of NFAT in T cells [49].
Activation of NFκB can also take place via PI3K [50],
which may offer an explanation for a difference in signal-
ing between GP (PI3K) and LPS (mitogen-activated kinase
signaling). This idea may be supported by another study
showing that despite the use of similar PRR, LPS and pep-
tidoglycan activated the IL-1RA gene through different
mechanisms/DNA-binding proteins and acted synergisti-
cally in combination, suggestive of signals which are not
equivalent in all parts [51].
Conclusion
In summary, our data demonstrated that in vitro glucan
phosphate induced a transcription factor binding and a
subsequent cytokine profile different from LPS and also
from TSST-1 and, moreover, switched a pro-inflammatory
TSST-1-induced response to an IL-1RA-mediated anti-
inflammatory reaction. Our results also generated new
insights into a very complex interplay of transcription fac-
tor binding to various known and newly identified sites in
the IL-1RA promoter (Fig. 8), which can be regulated dif-
ferentially by a fungal carbohydrate. Together with the in
vivo studies [22,37], our findings might support the con-
cept of protective effects mediated by glucan phosphate in
pro-inflammatory conditions, especially with a dysregu-
lated IL-1β/IL-1RA ratio [52,53].
Methods
Materials
Water soluble phosphorylated β-1→3-D-glucan (GP) was
prepared as done before [20]. The physicochemical char-
acteristics of GP were determined as reported previously
[20,26]. GP was dissolved in aqueous media, filter-steri-
lized (0.2 µm) and screened for endotoxin contamination
with the Endospecy assay (Seigakaku, Tokyo, Japan),
which is specific for endotoxin but does not respond to β-
1→3-D-glucans.
Isolation of human PBMC
Buffy coats were obtained from healthy blood donors in
compliance with the Helsinki declaration and with the
approval of the ethics committee of the University of Lue-
beck. The buffy coats were separated over a Ficoll-
Hypaque (Biochrom, Berlin, Germany) gradient [54,55].
Following isolation, PBMC were cultured at a final con-
centration of 3 × 106 cells/ml (for ELISA measurements)
or 5 × 106/ml (for gel shifts) or 1 × 106 cells/ml (for flow
cytometry) in RPMI 1640 medium (BioWhittaker, Heidel-
berg, Germany, LPS-free), containing 10% heat-inacti-
vated fetal calf serum (FCS, low-LPS, Invitrogen,
Karlsruhe, Germany), 1% penicillin (10000 U/ml), 1%
streptomycin (10000 µg/ml), and 1% 200 mM L-
glutamine (BioWhittaker).
Stimulation conditions
For induction of transcription factors and cytokines,
PBMC were cultured in a volume of 4 ml in sterile pyro-
gen-free 6-well culture plates (Falcon, Heidelberg, Ger-
many). Cultures were stimulated for 1 h (EMSA) or from
0 h to 48 h (ELISA) with 1 or 100 µg per 106 cells of GP,
with 250 ng/106 cells TSST-1 (Toxin Technologies, Sara-
sota, FL, USA) or with 250 ng/106 cells wild-type LPS from
Escherichia coli serotype 0111:B4 (Sigma, Munich, Ger-
many). In costimulatory experiments, PBMC were supple-
mented simultaneously with a combination of GP and
TSST-1 or with a combination of GP and LPS.
Oligonucleotides (Oligos) and 5'-32-P-Labeling
The complementary double-stranded (ds) oligonucle-
otides (oligos) from the TNFα, IL-8, IFNγ and IL-6 pro-
moters were synthesised from single stranded (ss) oligos
(illustrated in Table 1), (TIB Molbiol, Berlin, Germany)
and  32P-labeled with 5'γ-P-ATP (3,000 Ci/mmol, Amer-
sham, Braunschweig, Germany) using the Ready-To-Go-
Polynucleotide-Kinase Kit (PNK Kit, Pharmacia LKB,
Freiburg, Germany) according to the manufacturer's
instructions. To test the binding specificity of the oligos,
mutated oligos were used as an additional control. Muta-
tions in the P2 site of the IFNγ promoter [29] and in the κ
consensus sequence of the TNFα promoter [55] have been
reported to interfere with sequences, which seem to be
crucial for the binding of NFAT and NFκB proteins,
respectively. Afterwards, the ds oligos were purified via gel
filtration using Probe Quant G-50 Micro Columns (Phar-
macia) according to the manufacturer's instructions.
Preparation of nuclear extracts and electrophoretic 
mobility shift assays (EMSA)
Nuclear extracts of purified PBMCs were prepared accord-
ing to a technique described by Trede et al. [27] and mod-
ified for our experimental setup [56]. The intensity of
shifted bands was normalized to bands of unstimulated
controls. Competition experiments with labeled and
unlabeled mutated oligos of the cytokine promoter bind-
ing sites (see above) were carried out in order to prevent
non-specific binding to nuclear proteins. For such experi-
ments, an excess (5–50×) of unlabeled oligos was addedBMC Immunology 2006, 7:5 http://www.biomedcentral.com/1471-2172/7/5
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to the nuclear extracts. For specificity of binding, super-
shift assays for NFκB with a combined p65/50 antibody
were performed (data not shown). To exclude non-spe-
cific reactions, a 30-fold molar excess of Oct-1 DNA (unre-
lated DNA, Table 1) was used, which did not compete
with specific binding.
Immuno (Dot) blot
To determine whether the DNA binding proteins were
related to NFκB and NFAT, dot blots using a SRC96D SNS
minifold I dot blotter (Schleicher & Schüll, Dassel, Ger-
many) were performed with the following positive con-
trols and antibodies (all from Santa Cruz Biotechnology,
Heidelberg, Germany): positive controls (10 ng/dot):
NFκB p52 (80 kD) sc-4095WB, c-Rel (61 kD) sc-4030WB;
Jurkat nuclear extract, PMA-stimulated; primary antibod-
ies (1 µg/dot): anti-NFκB p50 (NLS) sc-114, anti-NFκB
p65 (A) sc-109, anti-NFκB p52 (447) sc-848, a rabbit pol-
yclonal IgG1 antiserum, anti-c-rel (N466) sc-272, anti-
NFATc2 (M-20) sc-1151, anti-NFATc1 (K-18) sc-1149,
two goat polyclonal IgG1 antisera; secondary antibodies
(0.8 µg/dot): goat anti-rabbit IgG AP-conjugate sc-2007,
and donkey anti-goat IgG AP-conjugate sc-2022. The
nuclear proteins were blotted onto a nitrocellulose mem-
brane (Bio-Rad). After blocking with PBS/3% BSA (Fluka,
Deisenhofen, Germany), the blot was incubated over-
night with the primary antibodies diluted 1:2000 in PBS/
1% BSA, washed again and incubated with the alkaline
phosphatase-conjugated secondary antibody (1:500 in
PBS/1% BSA). The blot was developed using the
Vectastain® staining kit (Vector Laboratories Inc. Burlin-
game, CA, USA).
Cytokine measurements
Supernatants of cell cultures were harvested 3, 6, 9, 12, 18,
24, 30, 36 and 48 hours after stimulation and stored at -
80 °C until used and thawed only once. IFNγ, TNFα, IL-1
and IL-6 were determined using an ELISA from Bender
Systems (Vienna, Austria), IL-1RA and IL-8 by an ELISA
from R&D Systems (Wiesbaden-Nordenstadt, Germany),
and TGFβ 1 using an ELISA as previously described [57].
Quantification of IL-2 as an indicator for the bioactivity of
IL-1 was done as previously described [46]. Samples were
diluted in the same buffer as that used for the standards.
All cytokines were quantified using an ELISA plate reader
(Anthos Labotec, Salzburg, Austria or Microplate Reader,
BioRad). Cytokine amounts were all within the range of
the standard curve. Only stimulation of PBMC observed
in donors showing no spontaneous cytokine release was
included in the statistics.
Inhibition of transcription factors
To inhibit translocation and binding of transcription fac-
tors to the IL-1RA promoter, PBMC were incubated for 1
h with each of the following substances (concentrations
were based upon 50% inhibition): 50 µg/ml of CAPE (caf-
feic-3,4-dihydroxycinnamic-acid-phenyl-ester), (Biomol,
Hamburg, Germany); 400 ng/ml cyclosporin A (Calbio-
chem-Merck Biosciences, Bad Soden, Germany); 10 µg/ml
cycloheximide (Santa Cruz Biotechnology) prior to incu-
bation with GP. Band shifts were determined after 1 h
incubation with GP as described before, including
mutated oligos for NFIL-6 (TTA CAA CAG TGG ATT GCG
ACA CTT AGT GGG) and NFATP2/3 (GGC GCA GAA AAG
GTA AAA TAT TTA CTA TCT) binding sites within the IL-
1RA promoter. PBMC RNA was isolated with an RNeasy
kit (Qiagen, Germany) and messenger RNA was tran-
scribed into cDNA with Reactin Ready First Strand kit
(Biomol) and analysed for IL-1RA and GAPDH transcripts
by PCR with a HotStart "sweet" PCR mastermix (Biomol)
(95°C, 30 sec, 55°C, 30 sec, 72°C, 30 sec, 25 cycles for IL-
1RA and 94°C for 30 sec, 50°C for 30 sec and 72°C for 45
sec, 25 cycles for GAPDH) following 18 h incubation with
GP. IL-1RA protein was measured in the supernatant by
ELISA after 24 h incubation with GP.
Statistical analysis
The Kolmogorow-Smirnov test was used to evaluate,
whether cytokine amounts and binding activities to tran-
scription factors were normally distributed. Correlation
coefficients and corresponding significances were ana-
lyzed by the Pearson test (normal distribution) or the
Spearman test (non-normal distribution). To compare
experimental data to a theoretical value (for example GP
+ TSST-1 vs GP/TSST-1 calc.) we calculated the sum of the
individual effects and added these values into Fig. 1B, 3,
4, 5, and 6. Significances of differences between experi-
mental data (for example GP vs LPS) as well as between
experimental data and theoretical values (for example GP
+ TSST-1 vs GP/TSST-1 calc.) were analysed using the Stu-
dent's t-test (normal distribution) or the Wilcoxon
Signed-Rank test (non-normal distribution), (SPSS for
Windows; SPSS Science Software, Erkrath, Germany).
Abbreviations
LPS, lipopolysaccharide; TSST-1, toxic shock syndrome
toxin 1; GP, glucan phosphate; PBMC, peripheral blood
mononuclear cells; PMN, polymorphonuclear neu-
trophils; LRE, LPS-responsive element; NF, nuclear factor;
IL, interleukin; BSA, bovine serum albumin; PBS, phos-
phate buffered saline; PMA, phorbol myristate acetate;
ATP, adenosine triphosphate; SEM, standard error of the
mean; n.s., non-significant (p > 0.05); CyA, cyclosporin A;
CHX, cycloheximide.
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